**Los Angeles**: As drug development costs soar, pharmaceutical firms are utilising AI solutions from Agilisium Consulting to enhance efficiency in GCCs. Their innovative tools address data management and compliance, aiming to streamline processes and reduce time-to-market for new drugs, particularly in the life sciences sector.
Pharmaceutical companies are increasingly leaning towards artificial intelligence to improve their drug development processes, which are notoriously expensive and fraught with risk. The median cost of bringing a single drug to approval can escalate to approximately $2.8 billion, largely due to failures encountered at various stages, including discovery, preclinical research, and late-stage clinical trials. Such financial burdens underscore the industry’s ongoing need for efficient data integration and management, particularly as they navigate diverse sources including clinical trials, real-world evidence, and patient data, often stored in silos that complicate analysis.
In this context, the Los Angeles-based Agilisium Consulting has emerged as a significant player by offering a suite of AI-focused solutions aimed at enhancing transformation in Pharmaceutical Global Capability Centers (GCCs). The company’s agentic AI solutions, such as the NextGen DataOps Platform and Insights Generation tools, are specifically designed to address the challenges faced by pharma companies in managing data and compliance.
Agilisium’s Content Generation tool is tailored for the life sciences sector, automating the creation of various critical documents including clinical trial protocols, regulatory submission dossiers, and drug safety reports. This tool ensures compliance with regulatory standards set by agencies such as the FDA and European Medicines Agency, thereby reducing the time required to bring new drugs to market while maintaining necessary accuracy.
The NexGen DataOps Platform harnesses AI to significantly enhance data management within the Life Sciences industry. Through smart agents, it offers real-time monitoring, trend analysis, and quick resolution of data issues. The model not only accelerates the pace at which insights are garnered but also optimises the data-sharing model within organisations, ensuring security is upheld.
Meanwhile, Agilisium’s Insights Generation solution allows life sciences firms to tap into an array of data sources, including electronic health records and genomic data, unlocking valuable insights that advance research and development efforts. The platform’s robust search capabilities alleviate time burdens associated with data retrieval, thereby enabling researchers to focus their efforts on critical analyses.
Agilisium has also emphasised the importance of data observability. Its Data Observability solution provides organisations with the capability to ensure data integrity, detect anomalies, and enhance decision-making processes through end-to-end visibility. This service integrates seamlessly with existing data architectures across various tools, presenting a comprehensive perspective on data health.
In a notable instance, Agilisium was able to rearchitect a Fortune 500 biopharma company’s data infrastructure, resulting in a significant increase in data processing efficiency and annual cost avoidance running into millions of dollars.
The company is not only making strides in the United States but is also placing a strong focus on its operations in India, where it has seen steady growth since 2014. With a workforce currently exceeding 700 employees, Agilisium aims to grow this number to 2,000 by the end of 2027. A key development is the establishment of a new facility at Hyderabad’s RMZ Spire campus, strategically situated in India’s pharma hub. This facility is intended to serve as both a Global Delivery Centre and a Gen AI Innovation Centre of Excellence, reinforcing Agilisium’s commitment to enhancing its GenAI solutions.
The growth trajectory of GCCs in India reflects broader trends in the IT and services sector, which currently employs around 1.6 million people. Projections estimate that the landscape will continue to evolve, with over 2,400 GCCs anticipated to provide employment for roughly 4.5 million individuals by 2030. The industry is expected to expand from a market size of $45 billion now to $110 billion within the same timeframe, buoyed by an increased hiring focus on fresh graduates and a dedication to reskilling existing talent in technology and AI.
Agilisium has established itself as a preferred partner of AWS, being recognised among the top 11 AWS partners globally with specific competencies in both Life Sciences Consulting and Generative AI Services. The company collaborates with over 20 Fortune 500 and Global 2000 biopharma companies, helping to evolve the entire pharmaceutical value chain through the innovative development of Gen AI solutions via Agilisium Labs, its dedicated innovation unit.
Source: Noah Wire Services
Subscribe to Industry Updates
